✦ LIBER ✦

Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma

✍ Scribed by Margaret A. Tempero; Anne Kessinger

Publisher: John Wiley and Sons
Year: 1982
Tongue: English
Weight: 206 KB
Volume: 21
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.2930210305

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Ten patients with advanced ovarian carcinoma were treated with hexa‐methylmelamine and melphalan after failing first‐line combination chemotherapy. In eight patients residual disease was evident only at second‐look laparotomy. Surgical debulking was accomplished in four patients but only two patients had residual disease of less than 2 cm. Two of these four patients are alive without evidence of disease at 20 and 24 months. The remaining patients have expired (median survival 6 months). The combination of hexamethylmelamine and melphalan after surgical debulking at second‐look operation may improve the salvage of patients with advanced ovarian carcinoma.

📜 SIMILAR VOLUMES

A randomized comparison of melphalan ver

A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma

✍ G. A. Omura; C. P. Morrow; J. A. Blessing; A. Miller; H. J. Buchsbaum; H. D. Hom 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 590 KB

Phase II study of irinotecan (CPT-11) as

Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma

✍ Donald Poon; Balram Chowbay; Yin-Bun Cheung; Swan-Swan Leong; Eng-Huat Tan 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Buserelin as primary therapy in advanced

Buserelin as primary therapy in advanced prostatic carcinoma

✍ Cary A. Presant; Mark S. Soloway; Sol S. Klioze; John W. Kosola; Alun L. Yakabow 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

Intraperitoneal bispecific antibody (HEA

Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma

✍ Alexander Marmé; Gudrun Strauß; Gunther Bastert; Eva-Maria Grischke; Gerhard Mol 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 135 KB

Bispecific antibody HEA125 x OKT3 was shown to redirect T lymphocytes toward carcinoma cells and to induce tumor cell lysis in vitro. Preclinical studies have demonstrated that tumor-associated lymphocytes (TAL) derived from malignant ascites can be used as effector cells with a high efficacy and wi

A Phase I trial of intravenous melphalan

A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma

✍ David M. Gershenson; Mitchell Morris; Thomas W. Burke; Charles Levenback; Judith 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

The primary purpose of this study was to establish the maximum tolerated dose (MTD) of intravenous melphalan in combination with paclitaxel and cisplatin plus granulocyte-colony stimulating factor (G-CSF) in patients with suboptimal advanced epithelial ovarian carcinoma or primary peritoneal carcino

Randomized trial of initial therapy with

Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results—Eastern Cooperative Oncology Group study E2878

✍ Scott Wadler; Beow Yeap; Steven Vogl; Paul Carbone 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 781 KB

## BACKGROUND. Following surgical debulking, most patients with International Federation of Gynecology and Obstetrics (FIGO) Stage 111 or IV carcinoma of the ovary receive treatment with combination chemotherapy. However, the optimal postsurgical therapy for ovarian carcinoma remains to be defined